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Arrhythmogenic cardiomyopathy (AC) is a heart muscle disease clinically characterized by life-threatening ventricular
arrhythmias and pathologically by an acquired and progressive dystrophy of the ventricular myocardium with
fibro-fatty replacement. Due to an estimated prevalence of 1:2000-1:5000, AC is listed among rare diseases.
A familial background consistent with an autosomal-dominant trait of inheritance is present in most of AC
patients; recessive variants have also been reported, either or not associated with palmoplantar keratoderma
and woolly hair. AC-causing genes mostly encode major components of the cardiac desmosome and up to
50 % of AC probands harbor mutations in one of them. Mutations in non-desmosomal genes have been also
described in a minority of AC patients, predisposing to the same or an overlapping disease phenotype. Compound/
digenic heterozygosity was identified in up to 25 % of AC-causing desmosomal gene mutation carriers, in part
explaining the phenotypic variability. Abnormal trafficking of intercellular proteins to the intercalated discs of
cardiomyocytes and Wnt/beta catenin and Hippo signaling pathways have been implicated in disease pathogenesis.
AC is a major cause of sudden death in the young and in athletes. The clinical picture may include a sub-clinical phase;
an overt electrical disorder; and right ventricular or biventricular pump failure. Ventricular fibrillation can occur at any
stage. Genotype-phenotype correlation studies led to identify biventricular and dominant left ventricular variants, thus
supporting the use of the broader term AC.
Since there is no “gold standard” to reach the diagnosis of AC, multiple categories of diagnostic information have been
combined and the criteria recently updated, to improve diagnostic sensitivity while maintaining specificity. Among
diagnostic tools, contrast enhanced cardiac magnetic resonance is playing a major role in detecting left dominant
forms of AC, even preceding morpho-functional abnormalities. The main differential diagnoses are idiopathic right
ventricular outflow tract tachycardia, myocarditis, sarcoidosis, dilated cardiomyopathy, right ventricular infarction,
congenital heart diseases with right ventricular overload and athlete heart. A positive genetic test in the affected
AC proband allows early identification of asymptomatic carriers by cascade genetic screening of family members.
Risk stratification remains a major clinical challenge and antiarrhythmic drugs, catheter ablation and implantable
cardioverter defibrillator are the currently available therapeutic tools. Sport disqualification is life-saving, since effort
is a major trigger not only of electrical instability but also of disease onset and progression. We review the current
knowledge of this rare cardiomyopathy, suggesting a flowchart for primary care clinicians and geneticists.Arrhythmogenic Cardiomyopathy- key points
summary
 AC is a rare (1:2000-1:5000) heredo-familial
cardiomyopathy, with an age-related penetrance
(usually adolescence-young adulthood)
 Clinical presentation is characterized by ventricular
arrhythmias at risk of sudden death. More rarely,* Correspondence: cristina.basso@unipd.it
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to heart failure is reported
 Generally referred as right ventricular disease,
recognition of left-dominant and biventricular
subtypes prompted the use of the broader term AC
 Effort is a trigger of disease onset and progression as
well as ventricular arrhythmias
 Disease causing genes mostly encode for
desmosomal proteins, although non-desmosomal
genes are also described
 The structural substrate of AC consists of
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the subepicardium. It accounts for morpho-
functional ventricular wall abnormalities that can be
absent in the early stages
 The in vivo demonstration of the structural
substrate of AC can be achieved directly by
endomyocardial biopsy or indirectly by contrast-
enhanced cardiac magnetic resonance (late–en-
hancement) and electrovoltage anatomic mapping
(low voltage area)
 Knowledge of phenocopies that can mimic AC is
essential to avoid misdiagnosis
 Shortcomings of 2010 update diagnostic criteria:
- left ventricular variant is almost missing
- contrast-enhanced cardiac magnetic resonance
and electrovoltage anatomic mapping are not yet
part of the diagnostic workup
- identification of a gene mutation in a patient
under evaluation is a major diagnostic criterion
(issues of mutation pathogenicity and
“genetic load”)
 Life-style modification (avoidance of strenuous
effort), anti-arrhythmic drugs, endocardial and
epicardial catheter ablation, and implantable
cardioverter defibrillator are the usual
therapeutic tools
 Risk stratification relies on phenotypic predictors
and recommendations for implantable cardioverter
defibrillator have been recently provided by a
consensus. Prognostic data are not yet available for
the left dominant variant
 Abnormal cell-cell adhesion, altered intracellular
signaling (Wnt and Hippo pathways) leading to
myocyte death and fibro-adipogenesis, gap junction
and ion channel remodelling are the pathogenetic
theories under investigation
 The identification of a compound known to
be an activator of the canonical Wnt signaling
pathway by high-throughput drug screening
in zebrafish JUP model opens the door for a
curative therapy
Background
Arrhythmogenic cardiomyopathy (AC) (OMIM #107970;
ORPHA247) is a rare disease of the heart muscle
characterized by a progressive myocardial dystrophy
with fibro-fatty replacement [1–4]. It is a genetically
determined cardiomyopathy caused by heterozygous
or compound heterozygous mutations in genes mostly
encoding proteins of the desmosomal complex (about
50 % of probands). Cases with a recessive trait of inherit-
ance have been reported, either associated or not with skin/
hair abnormalities [3, 4]. AC shows an age-related pene-
trance, manifesting with palpitations, syncope or cardiacarrest usually in adolescence or young adulthood [5] and
represents one of the major causes of sudden death (SD) in
the young and athlete [1, 6, 7]. High clinical and genetic
variability is reported. There is no a single gold standard for
the diagnosis, which is mainly based on functional and
structural alterations of the right ventricle (RV), fibro-fatty
replacement of the myocardium, depolarization and repo-
larization abnormalities, arrhythmias with the left bundle
branch block (LBBB) morphology and family history [8].
Genotype-phenotype correlation studies have recently iden-
tified clinical variants characterized by early dominant left
ventricular (LV) involvement, besides the classical RV vari-
ant, thus supporting the use of the broader term AC [3, 4,
9–11]. In this paper we will review clinical, pathologic and
genetic findings of AC, together with diagnosis and
treatment. The current knowledge on disease patho-
genesis will also be treated.
Disease names/synonyms
Arrhythmogenic Cardiomyopathy (AC, ACM), Arrhyth-
mogenic RV Cardiomyopathy (ARVC), Arrhythmogenic
RV Cardiomyopathy/Dysplasia (ARVC/D), Arrhythmo-
genic RV Dysplasia (ARVD).
Definition
More than 20 years elapsed since the 1995 WHO defin-
ition and classification of cardiomyopathies [12], the gen-
etic background has been discovered and new diagnostic
tools are now available. Thanks to genotype-phenotype
correlation, we know that the disease spectrum is wider
than previously thought, with LV involvement present and
even dominant at early stages. Thus, nowadays the
original disease definition could be updated as: “AC is
characterized by progressive fibro-fatty replacement of
ventricular myocardium, including RV and LV, with relative
sparing of the septum. Presentation with arrhythmias and
SD is common, particularly in the young. Mutations in
genes mostly encoding for desmosomal proteins are found
in about half of probands”.
Epidemiology
The estimated prevalence of AC in the general popula-
tion ranges from 1:2000 to 1:5000 [3, 5]. Considered in
the past an endemic disease in North East Italy (“Ven-
etian disease”), AC is now well recognized in human pop-
ulations of different ethnicity, but no data are available on
its prevalence across various countries. AC affects more
frequently males than females (up to 3:1), despite a similar
prevalence of carrier status between sexes, and becomes
clinically overt most often in the second-fourth decade of
life [3, 5]. More rarely, symptoms and signs can appear
before puberty or in the elderly. However, occasionally the
first clinical manifestations arise even in patients >70, but
the diagnosis is often missed because clinicians do not
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age-group [3].
Pathological findings
AC is a “structural” cardiomyopathy characterized by
dystrophy of the ventricular myocardium with replace-
ment by fibro-fatty tissue [1, 2] (Fig. 1). Myocardial atro-
phy occurs progressively with time, starts from the
epicardium and eventually extends to become trans-
mural. This entity should not be confound with Uhl’s
disease, a congenital heart defect in which the RV myo-
cardium fails to develop during embryonic life [9, 13].
The gross pathognomonic features of AC consist of RV
aneurysms, whether single or multiple, located in the
so-called “triangle of dysplasia” (i.e. inflow, apex and
outflow tract) [2, 14]. Nevertheless, grossly normal
hearts have been reported in whom only a careful histo-
pathology investigation can reveal AC features. Even
cases with isolated or predominant LV involvement [4]
are no so rare. Indeed, up to 76 % of the AC hearts stud-
ied at post-mortem disclosed a LV involvement, usually
limited to the subepicardium or midmural layers of theFig. 1 Histopathology of classical RV and left dominant AC variants
in AC patients who died suddenly. a transmural fibrofatty
replacement of the RV free wall b mid-mural subepicardial fibro-fatty
(mostly fibrous) replacement of the LV postero-lateral free wallpostero-lateral free wall [2, 15]. Hearts with end-stage
disease and congestive heart failure usually show mul-
tiple RV aneurysms and huge chamber dilatation, with a
higher prevalence of biventricular involvement, while
the ventricular septum is mostly spared [2].
Histological examination reveals islands of surviving
myocytes, interspersed with fibrous and fatty tissue [1, 2].
Fatty infiltration of the RV is not a sufficient morphologic
hallmark of AC [16, 17] and replacement-type fibrosis and
myocyte degenerative changes should be always searched
for. Myocyte necrosis is seldom evident and may be associ-
ated with inflammatory infiltrates [2, 18]. Myocardial in-
flammation has been reported in up to 75 % of hearts at
autopsy. An apoptotic mechanism of myocyte death has
been also proven [19, 20]. Rather than being a continuous,
ongoing process, disease progression may occur through
periodic “acute bursts” of an otherwise stable disease, as to
mimic myocarditis or myocardial infarction with normal
coronary arteries. In a desmoglein-2 (dsg2) transgenic ani-
mal model, myocyte necrosis was demonstrated to be the
key initiator of myocardial injury, triggering progressive
myocardial damage, followed by an inflammatory response
[21]. The detection of viral genomes let to advance an in-
fective viral etiology, but it is most likely that either viruses
are innocent bystanders or that myocardial cell degener-
ation may serve as a milieu favoring viral settlement [22].
Clinical findings and natural history
In adolescents or young adults, AC usually presents with
palpitations, syncope, or cardiac arrest. Then, premature
ventricular complexes (PVC) or ventricular tachycardia
(VT) with LBBB morphology and T-wave inversion in
V1- V3 leads on basal electrocardiogram (ECG) are the most
common index of suspicion. Less-common presentations
are RV or biventricular dilatation, with or without heart
failure symptoms, mimicking dilated cardiomyopathy. Clin-
ical manifestations vary with age and stage of disease. Men
usually develop a more severe phenotype, most likely be-
cause of the effect of vigorous sport activity on disease
onset and progression and influence of sex hormones.
Syncope, palpitations and ventricular arrhythmias are
the usual presenting symptoms also in the paediatric age
[23]. However, non-specific clinical features not infre-
quently consist of myocarditis or myocardial infarction
like-picture with chest pain, dynamic ST-T wave changes
on basal 12- lead ECG and myocardial enzymes release
with normal coronary arteries [3].
Four phases are recognizable along the natural history
of the classic AC variant: 1) “concealed”, with subtle RV
structural changes, with or without ventricular arrhyth-
mias; 2) “overt electrical disorder”, with symptomatic
life-threatening ventricular arrhythmias associated with
clear cut RV morpho-functional abnormalities; 3) “RV
failure”, due to progression and extension of RV disease;
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LV disease [24]. Electrical instability may lead to
arrhythmic SD any time during the course of the disease
[2, 5, 6, 25–27]. AC has been reported as the second
cause of SD in the young and the first cause in competitive
athletes in the Veneto Region of Italy [1, 6, 7]. The inci-
dence of SD ranges from 0,08 · to 3,6 % per year in adults
with AC [3, 5, 25–27]. While patients with an overt disease
phenotype more often experience scar-related re-entrant
VT, those with an early stage or a “hot phase” of the disease
may present with ventricular fibrillation (VF) due to on-
going myocyte death and reactive inflammation [27]. More
recently, gap junction remodelling and sodium channel
interference have been advanced in experimental models
as alternative substrates for life-threatening arrhythmias
even in the pre-phenotypic disease stage [28, 29].
AC diagnosis
No single gold-standard is available for AC diagnosis.
Multiple criteria are needed, combining different sources
of diagnostic information, such as morpho-functional
abnormalities (by echocardiography and/or angiography
and/or cardiac magnetic resonance-CMR), histopatho-
logical features on endomyocardial biopsy (EMB), ECG,
arrhythmias and family history, including genetics (Fig. 2).
The diagnostic criteria, originally put forward in 1994
[30], have been revised in 2010 to improve diagnosticFig. 2 Diagnostic tools to achieve a clinical diagnosis of classical RV AC. a,
and aneurysms; d tissue characterization through endomyocardial biopsy; e
and VT; f post-excitation epsilon wave in precordial leads V1-V3 (arrows); g
Family pedigree with autosomal dominant inheritance of the diseasesensitivity, but with the important prerequisite of main-
taining diagnostic specificity (Table 1) [8].
Quantitative parameters have been included and
abnormalities were defined, based on the comparison
with normal subject data. Moreover, T-wave inversion in
V1-V3, and VT with a LBBB morphology with superior
or indeterminate QRS axis (either sustained or no sus-
tained), have become major diagnostic criteria; and
T-wave inversion in V1-V2, in the absence of right bun-
dle branch block (RBBB), and in V1-V4, in the presence
of complete RBBB, has been included among the minor
criteria. Finally, in the family history category, the
confirmation of AC in a first-degree relative, by either
meeting current criteria or pathologically (at autopsy or
surgery), and the identification of a pathogenic mutation,
categorized as associated or probably associated with
AC, in the patient under evaluation are considered
major criteria. Because of the diagnostic implications,
however, caution is highly recommended since the
pathogenic significance of a mutation is increasingly
questioned (see genetic section) [8].
AC diagnosis in the pediatric age
AC diagnosis is exceptionally made below the age of 10
[23]. The diagnostic criteria in adults have been demon-
strated to be also valid in the pediatric age group, with
the exception of inverted T wave on right precordialb, c echocardiography, CMR and angiography showing RV dilatation
12-lead ECG with inverted T waves V1-V3, LBBB morphology PVCs
Signal-averaged ECG with late potentials (40 Hz high-pass filtering); h
Table 1 2010 Revised Task Force Criteria for AC
I. Global or regional dysfunction and structural alterations*
Major
By 2D echo
Regional RV akinesia, dyskinesia, or aneurysm
and 1 of the following (end diastole):
▪ PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA]≥ 19 mm/m2)
▪ PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 mm/m2)
▪ or fractional area change ≤ 33 %
By CMR
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
and 1 of the following:
▪ Ratio of RV end-diastolic volume to BSA ≥110 mL/m2 (male) or
≥100 mL/m2 (female)
▪ or RV ejection fraction ≤40 %
By RV angiography
Regional RV akinesia, dyskinesia, or aneurysm
Minor
By 2D echo
Regional RV akinesia or dyskinesia
and 1 of the following (end diastole):
▪ PLAX RVOT ≥29 to <32 mm (corrected for body size [PLAX/BSA] ≥16
to <19 m/m2)
▪ PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/BSA] ≥18
to <21 mm/m2)
▪ or fractional area change >33 % to ≤40 %
By CMR
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
and 1 of the following:
▪ Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 (male)
or ≥90 to <100 mL/m2 (female)
▪ or RV ejection fraction >40 % to ≤45 %
II. Tissue characterization of wall
Major
Residual myocytes <60 % by morphometric analysis (or <50 % if
estimated), with fibrous replacement of the RV free wall myocardium in
≥1 sample, with or without fatty replacement of tissue on EMB
Minor
Residual myocytes <60 % by morphometric analysis (or <50 % if
estimated), with fibrous replacement of the RV free wall myocardium in
≥1 sample, with or without fatty replacement of tissue on EMB
III. Repolarization abnormalities
Major
▪ Inverted T waves in right precordial leads (V1, V2, and V3) or beyond
in individuals >14 years of age (in the absence of complete RBBB QRS
≥120 ms)
Minor
▪ Inverted T waves in leads V1 and V2 in individuals >14 years of
age (in the absence of complete RBBB) or in V4, V5, or V6
▪ Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of
age in the presence of complete right RBBB
IV. Depolarization/conduction abnormalities
Table 1 2010 Revised Task Force Criteria for AC (Continued)
Major
▪ Epsilon wave (reproducible low-amplitude signals between end of QRS
complex to onset of the T wave) in the right precordial leads (V1 to V3)
Minor
▪ Late potentials by SAECG in ≥1 of 3 parameters in the absence of a
QRS duration of ≥110 ms on the standard ECG
▪ Filtered QRS duration (fQRS) ≥114 ms
▪ Duration of terminal QRS <40 μV (low-amplitude signal duration)
≥38 ms
▪ Root-mean-square voltage of terminal 40 ms ≤20 μV
▪ Terminal activation duration of QRS ≥55 ms measured from the nadir
of the S wave to the end of the QRS, including R’, in V1, V2, or V3, in
the absence of complete RBBB
V. Arrhythmias
Major
▪ Nonsustained or sustained VT of LBBB morphology with superior axis
(negative or indeterminate QRS in leads II, III, and aVF and positive in
lead aVL)
Minor
▪ Nonsustained or sustained VT of RVOT configuration, LBBB
morphology with inferior axis (positive QRS in leads II, III, and aVF and
negative in lead aVL) or of unknown axis
▪ >500 PVCs per 24 hours (Holter)
VI. Family history
Major
▪ AC confirmed in a first-degree relative who meets current Task Force
criteria
▪ AC confirmed pathologically at autopsy or surgery in a first-degree
relative
▪ Identification of a pathogenic mutation† categorized as associated or
probably associated with AC in the patient under evaluation
Minor
▪ History of AC in a first-degree relative in whom it is not possible or
practical to determine whether the family member meets current Task
Force criteria
▪ Premature SD (35 years of age) due to suspected AC in a first-degree
relative
▪ AC confirmed pathologically or by current Task Force Criteria in
second-degree relative
Two major, or one major and two minor, or four minor criteria: definite
diagnosis of AC. One major and one minor, or three minor criteria: borderline
diagnosis; One major, or two minor criteria from different categories:
possible diagnosis
* Hypokinesis is not included in this or subsequent definitions of RV regional
wall motion abnormalities for the proposed modified criteria
† A pathogenic mutation is a DNA alteration associated with AC that alters or
is expected to alter the encoded protein, is unobserved or rare in a large non-
AC control population, and either alters or is predicted to alter the structure or
function of the protein or has demonstrated linkage to the disease phenotype
in a conclusive pedigree
Abbreviations. BSA: body surface area; CMR: cardiac magnetic resonance; EMB:
endomyocardial biopsy; LBBB: left bundle- branch block; PLAX: parasternal
long-axis view; PSAX: parasternal short-axis view; PVC: premature ventricular
complex; RBBB: right bundle-branch block; RV: right ventricle; RVOT: RV outflow
tract; SD: sudden death; VT: ventricular tachycardia
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However, negative results are quite common before ado-
lescent growth is completed, due to absent or limited
morpho-functional phenotype, since AC usually shows an
age-related penetrance [3, 5]. Follow-up by non-invasive
clinical investigation of children who have a family and/or
personal history suspicious for AC or healthy gene carriers
is recommended on a regular basis, to monitor the pend-
ing disease onset in the pubertal period.
Left dominant AC diagnosis
The 2010 criteria acknowledge that RV AC is the best
recognized variant of a broad disease spectrum, that in-
cludes also LV and biventricular subtypes [8]. While the
revised criteria easily catch the classical RV variant, there
is lack of specific diagnostic guidelines for non-classical
disease patterns, thus explaining the under-recognition
of the LV one. The only step forward with respect to the
1994 criteria [30] is that patients with a moderate-to-
severe LV dysfunction can now be diagnosed as affected
by AC. ECG abnormalities such as lateral or inferolateral
T-wave inversion (leads V5, V6, LI, and aVL), low voltage
QRS complex on peripheral leads and RBBB/poly-
morphic ventricular arrhythmias suggest a left-side
involvement [31–33] (Fig. 3 and Table 2). Contrast-
enhanced CMR is the more sensitive imaging tool to catch
LV involvement by non-invasive tissue characterization
[33–35]. Late gadolinium enhancement is in fact a far
more-sensitive indicator of even early or minor left-sided
disease, and is frequently detected in a wall segment with-
out a concomitant morphofunctional abnormality, thusFig. 3 Electrocardiographic features of classical RV vs left dominant AC vari
AC variant: negative T waves in V4-V6 and inferior leadspreceding the onset of LV dysfunction or dilatation. Typic-
ally, LV late gadolinium enhancement involves the infe-
rolateral and inferoseptal regions, and affects the
subepicardial or midwall layers (Fig. 4). Differential diag-
nosis with dilated cardiomyopathy is mandatory for
risk-stratification and familial evaluation purposes. The
propensity to electrical instability that exceeds the degree
of ventricular dysfunction is typical of left dominant AC,
at difference from dilated cardiomyopathy where life-
threatening ventricular arrhythmias usually occur in the
context of systolic dysfunction with low ejection frac-
tion (<35 %). Moreover, a regional rather than global in-
volvement is more in keeping with AC, particularly
when RV abnormalities are also prominent. Thus, a
revision of the 2010 Task Force criteria is needed to
fill the gap by incorporating features suggesting LV
involvement.
Differential diagnosis
Common dilemmas in differential diagnosis include
myocarditis, sarcoidosis, RV infarction, dilated cardio-
myopathy, Chagas disease, Brugada syndrome, pulmon-
ary hypertension and congenital heart disease with right
chambers overload [3]. Moreover, one of the main clinical
challenge is still differentiation of AC from idiopathic RV
outflow tract VT, which is usually benign and non-familial
(Table 2) [36]. EMB can be crucial both to rule out the
phenocopies such as myocarditis and sarcoidosis, espe-
cially when dealing with sporadic forms, and in the setting
of negative or doubtful CMR and/or electroanatomic
voltage mapping [37]. The latter is an invasiveants. a classical RV AC variant: negative T waves in V1-V3; b left dominant
Table 2 Main clinical features of RVOT tachycardia, RV AC and LV AC
Idiopathic RVOT tachycardia RV AC LV AC
Family history - + +
Cardiocutaneous
syndrome
- + Naxos syndrome + Carvajal syndrome
Desmosomal gene
mutations
- up to 60 % about 30 %
12 lead ECG Normal Normal or T-wave inversion V1-V3/V4 Normal or T-wave inversion
infero-lateral leads
RBBB varying degree ε wave II,III, aVF, and/or V4-V6, I,
aVL
S wave delayed upstroke, ε wave V1-V3 Low voltage QRS complexes
SAECG - + -+
Arrhythmia LBBB morphology PVCs/ventricular arrhythmias
with an inferior axis (R wave positive in leads II
and III and negative in lead aVL)
LBBB morphology PVCs/ventricular




Single VT morphology, QRS axis inferior Multiple VT morphologies common Multiple VT morphologies
common
Inducibility at EPS +- + NA
Ventricular volumes Normal or RVOT mild dilatation Normal or mild, moderate or severe RV
dilatation ± dysfunction,
Normal or mild, moderate or
severe LV dilatation ± dysfunction
RV/LV volume ≥1.2 RV/LV volume <1
Other imaging
findings
- Localized dilatation, WMA, and/or aneurysms
in RV
Localized dilatation, WMA,
and/or aneurysms in LV
Non-compacted appearance
EMB - + -+
CMR - Fat in RV myocardium LE in LV myocardium
(subepicardial-midmural)




SCD risk - + +
Abbreviations. CMR: cardiac magnetic resonance; EMB: endomyocardial biopsy; EPS: electrophysiologic study; LBBB: left bundle branch block; LE: late enhancement;
LV: left ventricle; RBBB: right bundle branch block; RV: right ventricle; RVOT: right ventricular outflow tract; SAECG: signal averaged ECG; SCD: sudden cardiac death;
VT: ventricular tachycardia; WMA: wall motion abnormalities
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patients with suspected AC, in the setting of ventricular
arrhythmias of RV origin, and/or when contrast-enhanced
CMR is negative or doubtful in terms of RV involvement
(Fig. 5) [36, 38]. The abnormal low-voltage areas found in
AC patients correspond to the loss of electrically active
myocardium caused by fibrofatty replacement (“electrical
scars”). Noteworthy, because of the wavefront progression
of RV fibro-fatty replacement from the epicardium to the
endocardium, scar tissue in non-advanced stages may be
confined to epicardial/midmural layers, sparing (or reach-
ing focally) the endocardial region. Thus, bipolar endocar-
dial voltage mapping of the RV free wall may underestimate
or miss nontransmural low-voltage areas [39].
Finally, in people performing sport activity, AC should
be distinguished from so-called “athlete heart”, i.e.
physiological adaptation to training with hemodynamic
overload. RV enlargement, ECG abnormalities and ar-
rhythmias are well documented in endurance athletes,
reflecting the increased hemodynamic load during exer-
cise [3, 40, 41]. Global RV systolic dysfunction and/orregional wall motion abnormalities, such as bulgings or
aneurysms, are in keeping more with AC than physio-
logic ventricular enlargement. The absence of overt
structural changes of the RV, frequent PVCs or inverted
T waves in precordial leads all support a benign
nature.
AC genes/mutations and diagnostic implications
In 1982, Marcus et al. advocated the inherited nature of
AC, with the description of two affected adult cases in
the same family [14]. The Padua group then demon-
strated that the classical inheritance pattern of AC is
autosomal dominant with variable expression and age-
dependent penetrance [5, 42]. Inter- and intra-familial
phenotype diversity is frequent in AC, with co-existence
of both the classic RV and dominant LV pattern in the
same family and/or life-threatening ventricular arrhyth-
mias in probands vs a more favorable prognosis in rela-
tives [5, 31, 32]. The first disease-causing gene [43], i.e.
the plakoglobin gene (JUP), was identified in a fully
penetrant autosomal-recessive form of AC associated
Fig. 4 Contrast enhanced CMR of classical RV (a, b) vs left dominant (c, d) AC variants. a, b Four-chamber and short axis views: widespread RV late
gadolinium enhancement with septal and LV involvement is notable; c, d Four chamber and short axis views: late gadolinium enhancement with a
mid-mural and sub-epicardial stria is visible in the inferior LV wall
Pilichou et al. Orphanet Journal of Rare Diseases  (2016) 11:33 Page 8 of 17with palmoplantar keratosis, also known as Naxos or
cardiocutaneous syndrome [44]. Subsequently, muta-
tions of the desmoplakin (DSP) gene were found to
cause another autosomal recessive cardiocutaneous syn-
drome, i.e. Carvajal syndrome [45]. Soon after, heterozy-
gous mutations in the same gene were identified in a
dominant form of AC without hair/skin abnormalities
[46]. To-date, 11 disease genes have been linked to the
AC phenotype, highlighting genetic heterogeneity. Most
of mutations in dominant forms have been identified in
desmosomal genes including DSP, plakophilin-2 (PKP2),
desmoglein-2 (DSG2), desmocollin-2 (DSC2) and JUP
[43, 46–50] (Table 3). Only isolated reports showed
causal mutations in non-desmosomal genes, such as
transmembrane protein 43 (TMEM43), desmin (DES),
titin (TTN), Lamin A/C (LMNA), phospholamban
(PLN) and αT-catenin (CTNNA3), sometimes with a
clinical phenotype similar but not identical to AC, as to be
considered phenocopies or overlap syndromes [51–56].
Moreover, mutations in the regulatory region of trans-
forming growth factor beta-3 gene have also beenreported [57], but their pathogenicity is still controversial.
Finally, ryanodine receptor 2 gene mutations are associ-
ated with catecholaminergic polymorphic VT (CPVT-see)
rather than with AC, as originally considered [58].
Thus, most of pathogenic mutations address structural
proteins that are involved in the organization of the in-
tercalated disc, which has been described as containing a
mixed-type junctional structure (the so-called area com-
posita) (Fig. 6) [59]. Comprehensive exonic sequence
analysis of the known desmosomal AC-related genes
currently identifies approximately 50 % of AC probands
[60–63]. The most commonly defective AC gene is
PKP2 (10–45 %), followed by DSP (10–15 %), DSG2 (7–
10 %) and DSC2, JUP (1–2 %). About 10–25 % of AC
patients are compound and heterozygous mutation
carriers [60, 65, 66] (Fig. 7). Founder mutations in both
desmosomal and non-desmosomal encoding genes have
been reported [53, 64, 65].
The inheritance pattern of AC is more complex than
previously appreciated, with frequent requirement for more
than one ‘hit’ for fully penetrant disease [60, 61, 66, 67].
Fig. 5 Electroanatomic voltage mapping vs. contrast enhanced CMR in AC. The fibro-fatty scar pathognomonic of AC is indirectly identifiable through
either electroanatomic voltage mapping, as low-voltage areas (normal myocardium:purple color), or CMR, as late-enhancement area. While the
former is superior in detecting the RV involvement (a, d), the latter is often the only tool able to detect the frequent LV involvement (b, c, e, f)
(from Ref 34, with permission)
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sive-like” inheritance pattern, based on the fact that AC
probands often carry homozygous or compound heterozy-
gous variants in the same gene, or digenic/oligogenic
variants in a cluster of desmosomal genes.
Nowadays, the pathogenicity of missense and radical
(nonsense, frameshifts, splice sites etc) mutations in car-
diac diseases and specifically in AC is a matter of debate.
Recent studies have shown that stop-coding in disease-
causing genes are more pathogenic than missense muta-
tions, since the former are causing alteration of protein
length and conformation, leading to haploinsufficiency
due to protein instability [67–70]. Entire PKP2 exons or
even whole gene deletions have been recently described
in AC families with a frequency of approximately 2 %
[71–73]. These data are further stressing the question
whether haploinsufficiency is enough to determine the
disease phenotype.
Genotyping success rate in AC varies according to co-
hort location and ethnicity, sequencing techniques, selec-
tion criteria and the stringency of the standards by which
mutations are considered causal. An allelic frequency lower
than 0.02–0.05% is considered pathogenic or likely patho-
genic. With the routine use of Next Generation Sequen-
cing, the analysis of large panel of genes may lead to the
identification of a high number of sequence variants withuncertain clinical significance. Thus, genetic testing and its
interpretation should be performed in dedicated AC
cardio-genetic centers, with pre- and post-counseling facil-
ities. Given that the prevalence of causal genes and muta-
tions has yet to be determined, a negative genetic test does
not exclude a genetic predisposition. The major advantage
of a positive genetic test in the affected AC proband
consists in the possibility to identify early asymptomatic
carriers by cascade genetic screening of family members.
Finally, although prenatal diagnosis through amniocentesis
is feasible, its application in many countries is subjected
to ethical and legal issues; this is even more for pre-
implantation diagnosis, which is a long procedure re-
stricted to severe and untreatable diseases.
Management and treatment
The most important goals of clinical management of AC
patients comprise: 1) reduction of mortality, either by
arrhythmic SD or death due to heart failure; 2) prevention
of disease progression leading to RV, LV or biventricular
dysfunction and heart failure; 3) attenuation of symptoms
and improvement of quality of life by decreasing or sup-
pressing palpitations, VT recurrences or implantable cardi-
overter defibrillator (ICD) discharges (either appropriate or
inappropriate); and 4) reducing heart failure symptoms and
increasing exercise capacity [74]. The AC management
Table 3 Genetic background of AC
MIM entry Locus Disease gene Gene Mode of
transmission
Author, year [Reference] Comment
Desmosomal genes
#611528 17q21.2 Plakoglobin JUP AD/AR McKoy et al. [43], AR form: Cardiocutaneous syndrome
#601214
#607450 6p24.3 Desmoplakin DSP AD/AR Rampazzo et al. [46], AR form: Cardiocutaneous syndrome
#605676
#609040 12p11.21 Plakophilin- 2 PKP2 AD/AR Gerull et al. [47],
#610193 18q12.1 Desmoglein-2 DSG2 AD/AR Pilichou et al. [48],
#610476 18q12.1 Desmocollin-2 DSC2 AD/AR Syrris et al. [49],
Non-desmosomal genes
#600996 1q43 Cardiac Ryanodine Receptor 2 RYR2 AD Tiso et al. [58], CPVT (AC phenocopy)
#107970 14q24.3 Transforming growth factor-beta-3 TGFB3 AD Beffagna et al. [57], Modifier?
#604400 3p25.1 Transmembrane Protein 43 TMEM43 AD Merner et al. [51],
2q35 Desmin DES AD Van Tintelen et al. [52], Overlap syndrome (DC and HC
phenotype, early conduction disease)
6q22.31 Phospholamban PLN AD Van der Zwaag et al. [53],
2q31.2 Titin TTN AD Taylor et al. [54], Overlap syndrome
(early conduction disease, AF)
1q22 Lamin A/C LMNA AD Quarta et al. [55], Overlap syndrome
#615616 10q21.3 alpha-T-catenin CTNNA3 AD Van Hengel et al. [56],
Abbreviations. AD: autosomal dominant; AF: atrial fibrillation; AR: autosomal recessive; CPVT: catecholaminergic polymorphic ventricular tachycardia; DC: dilated
cardiomyopathy; HC: hypertrophic cardiomyopathy
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treatment, catheter ablation, ICD implantation, and excep-
tionally heart transplantation [75, 76]. Figure 8 summarizes
the flow chart for clinical treatment of AC.
Before any therapy is undertaken, life-style modifica-
tion should be pursued. Sport activity is associated with
an increased risk of SD, thus supporting the concept that
avoiding effort is “per se” life-saving [1, 6, 7]. Recently, it
has been demonstrated that endurance sports and fre-
quent exercise increase age-related penetrance, risk of
VTs, and occurrence of heart failure in AC desmosomal
gene carriers [77, 78]. Pregnancy is generally well tolerated
but a pre-conception evaluation is mandatory for individu-
alized arrhythmic risk stratification and prescription of the
best antiarrhythmic therapy [79]. β–blockers treatment is
better since no teratogen effects are known but they may
be associated with intrauterine growth retardation and
neonatal bradycardia or hypoglycemia [75].
Different antiarrhythmic drugs have been employed,
such as sodium blockers, β-blockers, sotalol, amiodarone,
verapamil alone or combinations. Wichter et al. [75] re-
ported various efficacy rates by demonstrating that sotalol
in a dosage of 320-480 mg/day is the most powerful anti
arrhythmic drug for inducible and non-inducible VT in
AC patients; amiodarone is less effective and has a high
risk of extracardiac side effects during long-term follow-
up; β-blockers are effective only in non-inducible patients.
Co-administration of more than one drug should beavoided. However, contradictory data regarding the effect-
iveness of empiric anti-arrhythmic drugs have been pub-
lished, showing either a higher efficacy of amiodarone or
inefficacy of anti-arrhythmic drugs against ICD interven-
tion and SD [76, 80]. Differences in the study populations,
drug doses, therapeutic approach (empiric vs. guided by
electrophysiologic study/Holter) and follow-up duration
may explain the divergence [80].
Catheter ablation of the re-entry circuit is a non
pharmacological therapeutic option for AC patients who
have VT. In fact, VT is the result of a scar-related macro-
reentry circuit due to RV fibro-fatty replacement, which is
suitable for mapping and interruption by catheter ablation
[81–84]. Catheter ablation may be guided by either con-
ventional electrophysiology or substrate-based mapping.
Linear ablation lesions connecting or encircling ventricu-
lar scar areas obtain the isolation of the re-entry circuit. In
the presence of a large RV scar burden and/or in patients
with VT recurrence, combined endo- and epi- substrate-
based VT ablation, incorporating scar dechanneling tech-
nique, would increase the short- and long-term success
rate. However, the epicardial approach has a significant
procedural complication rate (up to 8 %) and should be
always performed in high volume referral centers [84].
ICD therapy is the first line approach for the highest-
risk patients, whose natural history is typically character-
ized by the risk of SD [27, 80, 85–87]. Data obtained from
either primary or secondary prevention studies indicate
Fig. 6 Cadherin-based cell-cell junctions in the cardiomyocytes. Area composita is a mixed-type junctional structure composed of both desmosomal
and adherens junctional proteins. Both αE-catenin (αE-cat) and αT-catenin (αT-cat) are present in the area composita at the cardiac inter-
calated disc, but only αT-catenin was shown to interact directly with PKP2. β-cat: β-catenin; PKG: Plakoglobin; PKP2: Plakophilin-2; DPK: Desmoplakin;
IF: Intermediate filaments (From Ref 59, modified)
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high-risk AC patients, with an estimated mortality reduc-
tion ranging from 20 to 30 %. Overall, 48–78 % of patients
received appropriate ICD interventions during the mean
follow-up period of 2–7 years after implantation [27, 87].
The published studies on ICD therapy in AC patients have
provided also valuable information about the risk predic-
tors for VF or VT triggering appropriate ICD discharges
during follow-up. A stronger predictor of a life-saving ICD
intervention was aborted SD due to VT/VF and syncope.
Other risk factors associated with an increased risk of ap-
propriate ICD interventions included hemodynamicallyFig. 7 Cascade family segregation and clinical screening is mandatory to d
AC. Black, white, and hatched symbols represent clinically affected individu
respectively. Presence (+) or absence (−) of 2 desmoglein-2 (DSG2) mutatio
case. b Criteria of testing mutation pathogenicity. Top- Missense mutation c.9
population (Minor Allele Frequency-MAF), evolutionary conservation of amino
mutation molecular assay showing 2 different trascripts. (modified from Ref.48well tolerated VT, either sustained or non-sustained, se-
vere RV and/or LV dysfunction, young age, proband status,
frequent polymorphic PVCs (≥1000/24 h), and inducibility
at programmed ventricular stimulation (PVS). The pres-
ence of multiple risk factors increases the likelihood of ap-
propriate ICD therapy. Most importantly, asymptomatic
probands and relatives without relevant risk factors as well
as healthy gene carriers showed a low rate of arrhythmic
events over a long-term follow-up, regardless of family his-
tory of SD. Despite well-known ICD benefit on survival,
disadvantages are related to the lead and device-
related complications as well as the inappropriate ICDefine gene mutation association with the disease. a Family pedigree of
als, unaffected individuals, and individuals of unknown disease status,
ns (c.991 G > A and c.1881 -2A > G) is indicated. Arrow indicate index
91 G > A showing aminoacid residue change, absence in large control
acid residues and in silico prediction algorithms. Bottom- splicing site
)
Fig. 8 Flow chart for clinical treatment of patients affected by AC (modified from Ref.74). On the left, management of heart failure (HF); on the right,
management of ventricular arrhythmias and prevention of sudden death (SD) accordingly to the SD risk category. Abbreviations. AA: antiarrhythmic
ICD : Implantable cardioverter defibrillator; VT : ventricular tachycardia; VF : ventricular fibrillation; Gen+/Phen- : Genotype positive/phenotype negative
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is usually caused by sinus tachycardia or atrial tachy-
arrhythmia [27, 87]. The inappropriate interventions
are painful and, especially in young patients, may
have a severe psychological impact hindering the
compliance to ICD therapy. When the incidence of
inappropriate ICD discharges is too high, the patients
can take advantage by appropriate ICD reprogramming
and/or co-administration of β-blockers therapy.
Cardiac transplantation
AC patients with severe, refractory biventricular heart fail-
ure or unmanageable VTs may become candidate to heart
transplantation. The most common indication for cardiac
transplantation is heart failure, and, in less than one-third
of patients, unbearable ventricular arrhythmias [3, 88].
Risk stratification
Arrhythmic risk stratification relies on phenotypic pre-
dictors, such as previous cardiac arrest due to VF,
sustained VT, unexplained syncope, severe RV or LV
dilatation/dysfunction, compound and digenic heterozy-
gosity of desmosomal gene mutations, low QRS ampli-
tude, QRS fragmentation, male gender, young age at time
of diagnosis, proband status, inducibility at PVS, burden
of electroanatomic scar and scar-related fractioned elec-
trograms, extent of T wave inversion across precordial
and inferior leads on ECG. In a recent document on risk
stratification and treatment of AC [87], indications for
ICD implantation were determined by consensus taking
into account the statistical risk, the general health,
the socioeconomic factors, the psychological impact andthe adverse effects of the device. The flow chart is repre-
sented in Fig. 9.
Noteworthy, these recommendations apply to the
classical RV AC variant and prognostic data are not
yet available in LV AC, which is increasingly detected by
contrast-enhanced CMR.
Pathogenesis of AC
Transgenic animal models that mimic the human AC
phenotype (mice and zebrafish) and induced pluripotent
stem cells (iPSCs) from affected patients are useful tools to
explore how the mechanical and/or functional disruption
of cell junctions by mutant desmosomal proteins leads to
cardiomyocyte death and subsequent repair with fibrous
and fatty tissue.
Abnormal cell-cell adhesion
Desmosomes mediate cell–cell adhesion through three
families of proteins, i.e. the armadillo proteins (junction
plakoglobin and plakophilins), cadherins (desmocollins
and desmogleins), and plakins (desmoplakin). Even be-
fore the discovery of desmosomal genes in AC, electron
microscopy studies demonstrating intercalated disc re-
modelling first raised the hypothesis of an abnormal
cell-cell adhesion in disease pathogenesis [89, 90]. More
recently, Sato et al., using monolayers of neonatal rat
ventricular myocytes in which PKP2 was silenced and
subjected to a defined mechanical intervention, demon-
strated a reduced cell-cell adhesion [91]. However, when
expressing mutant forms of either PKP2 or JUP, cells ex-
hibited abnormal signaling in response to mechanical
stress, but showed a preserved intercellular adhesion,
Fig. 9 Flow chart of risk stratification and indications to ICD in AC. The estimated risk of major arrhythmic events in the high-risk category
is >10 %/year, in the intermediate-risk category ranges from 1 to 10 %/year, and in the low-risk category is <1 %/year. The high risk category includes
patients who experienced cardiac arrest due to VF or sustained VT and most benefit from ICD (estimated annual event rate >10 %/year). The low risk
category comprises probands and relatives without risk factors as well as healthy gene carriers (estimated annual event rate <1 %/year), who do not
require any treatment. The intermediate risk category includes AC patients with ≥1 risk factors, except those mentioned in the high risk category
(estimated annual event rate between 1 and 10 %/year). The decision to implant an ICD in these patients should be made on individual basis (from
Ref.87, with permission). Abbreviations. SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia; RV: right ventricle; LV: left ventricle
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AC pathogenesis [92]. At the same time, Asimaki et al.
[93] demonstrated that a reduced junctional signal for
JUP appears to be a hallmark of the disease in myocar-
dial samples from AC patients, pointing to its possible
role in intracellular signaling rather than adhesion, as
suggested by other groups [94, 95].
Abnormal intercellular junction proteins and intracellular
signaling
The role of intracellular signaling, with the Wnt signaling
pathway suppression leading to adipogenesis, as a conse-
quence of the abnormal distribution of intercalated disc
proteins, was first demonstrated by Marian group [94]. In a
Dsp-deficient mouse model, the authors showed suppres-
sion of the canonical Wnt/β-catenin/Tcf/Lef pathway, a
known regulator of adipogenesis, fibrogenesis and apop-
tosis. Knockdown of DSP in HL-1 cells causes the trans-
location of JUP into the nucleus, where it interferes with
β-catenin/TCF transcriptional activity, leading to an adipo-
genic switch. Thereafter, by using genetic fate-mapping
methods, the same group demonstrated that most of the
adipocytes in AC originate from cardiac progenitors cells of
the embryonic second heart field [96]. Furthermore, in mice
overexpressing cardiac truncated JUP, suppression of the ca-
nonical Wnt signaling pathway and induction of proadipo-
genic genes expression due to nuclear translocation of JUP
led to adipogenesis in c-kit + cardiac progenitor cells [97].
Recently, also the Hippo/YAP signaling pathway has
been associated to AC pathogenesis. In the nucleus, YAPinteracts with β-catenin to drive Wnt-related gene ex-
pression. In AC patients myocardial samples, mouse
model and pkp2 knockdown HL-1 myocytes, Chen et al.
[98] demonstrated aberrant activation of the Hippo kin-
ase cascade resulting into phosphorylation and cytoplas-
mic retention of YAP; this causes β-catenin and JUP
cytoplasmic sequestration, with further suppression of
the canonical Wnt signaling leading to enhanced myo-
cyte death and fibro-adipogenesis.
Cellular reprogramming of patient-derived somatic
cells (i.e. dermal fibroblasts) into iPSCs has enabled the
generation of human cardiomyocytes for in vivo model-
ing. Among the others, Kim et al. [99], by studying
iPSCs-derived cardiomyocytes from AC patients with
PKP2 mutations, demonstrated that the abnormal JUP
nuclear translocation and decreased β-catenin activity is
insufficient to reproduce the pathologic phenotype in
standard conditions. Only the induction of an adult-like
metabolism in a lipogenic milieu co-activated PPAR-γ
pathway with lipogenesis, apoptosis and calcium-
handling deficit [99].
Noteworthy, all transgenic experimental animal
models and iPSC-derived cardiomyocytes demon-
strated only abnormal “lipogenesis”, but not adipocyte
formation/transdifferentiation. Thus, cells other than
cardiomyocytes must be involved in the abnormal
adipogenesis and fibrosis which is an essential feature
of AC phenotype [100]. A role of cardiac mesenchy-
mal stromal cells as a source of adipocytes in AC has
been recently suggested [101].
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Desmosomes, gap junctions and sodium channels act as
a functional triad in which changes in the composition
of one constituent can affect the function and integrity
of the others [4]. Diminished expression of connexin-43
at intercellular junction was demonstrated in most of
AC cases, suggesting that impaired mechanical coupling
might also account for abnormal electrical coupling
through gap-junction remodelling. Moreover, cardiac so-
dium current was found to be reduced in experimental
models of AC [28, 29, 102–104]. These findings led to
hypothesize that life-threatening ventricular arrhythmias
could occur in AC patients, even preceding the struc-
tural abnormalities (pre-phenotypic stage) due to elec-
trical uncoupling and reduced sodium current. However,
this hypothesis remains to be proven in human AC pa-
tients, where only a reduced immunoreactive signal at
intercalated disc for the major protein subunit of the so-
dium channel Nav1.5 has been demonstrated [103].
From experimental models to target therapy
In a transgenic zebrafish model of AC with cardiac specific
expression of human JUP deletion, high-throughput drug
screening identified SB216763, a compound able to prevent
heart failure and normalize survival [104]. Its efficacy has
been further supported by experiments in neonatal rat ven-
tricular myocytes expressing the same JUP mutation and in
cardiac myocytes derived from iPSCs of two PKP2 muta-
tion carriers. Treatment with SB216763 restored the sub-
cellular distribution of JUP, connexin-43 and Nav1.5 and of
SAP97, a protein known to mediate the forward trafficking
of Nav1.5 and Kir2.1. Noteworthy, SB216763 was already
known as an activator of the canonical Wnt signaling path-
way and this study confirms an abnormal protein trafficking
at the intercalated discs, rather than altered protein produc-
tion in AC. These data, together with those by Lombardi
et al. [96] and by Kim et al. [99], who were able to prevent
cell degenerative changes using another Wnt activator,
i.e. 6-bromoindirubin-3’-oxime, open the door to the
identification of a curative therapy in AC, by targeting a
final common pathway of disease pathogenesis.
Conclusions
Many advances have been made in the clinical diagnosis
and management of AC in the last 10 years. While the
classical RV variant of AC is nowadays easily recognized,
thanks to updated diagnostic criteria, LV variants are
increasingly identified, thus supporting the use of the
broader term AC. Abnormal trafficking of intercellular
proteins and Wnt/beta catenin and Hippo signaling path-
ways have been implicated in the pathogenesis of this
inherited rare cardiomyopathy, which is mostly due muta-
tions of genes encoding for intercalated disc proteins. On-
going research is focused on the understanding of diseasepathobiology in search of a curative therapy able to stop
disease progression.
Abbreviations
AC: Arrhythmogenic Cardiomyopathy; ARVC/D: Arrhythmogenic RV
Cardiomyopathy/Dysplasia; BSA: body surface area; CMR: cardiac magnetic
resonance; CTNNA3: αT-catenin; DES: desmin; DSC2: desmocollin-2;
DSG2: desmoglein-2; DSP: desmoplakin; ECG: electrocardiography;
EMB: endomyocardial biopsy; EPS: electrophysiologic study; iPSCs: induced
pluripotent stem cells; JUP: plakoglobin; LBBB: left bundle branch block; LE: late
enhancement; LMNA: Lamin A/C; LV: left ventricular; PKP2: plakophilin-2;
PLAX: parasternal long-axis view; PLN: phospholamban; PSAX: parasternal short-
axis view; PVC: premature ventricular complex; PVS: programmed ventricular
stimulation; RBBB: right bundle-branch block; RV: right ventricular; RVOT: RV
outflow tract; RYR2: ryanodine receptor 2; SAECG: signal averaged ECG;
SCD: sudden cardiac death; SD: sudden death; TGFB3: transforming growth
factor beta 3; TMEM43: transmembrane protein 43; TTN: titin; VF: ventricular
fibrillation; VT: ventricular tachycardia; WMA: wall motion abnormalities.
Competing interests
The authors declare that they have no competing intetests.
Authors’ contributions
KP clinical geneticist in charge of genetic test and counseling in AC patients,
wrote the manuscript; GT project leader of the AC investigation; BB clinical
cardiologist in charge of family screening and AC database, IR clinical
cardiologist in charge of echocardiographic screening of patients, EL biologist is
in charge of next generation sequencing in AC probands and genetic database;
FM cardiac electrophysiologist in charge of invasive diagnosis and therapy;
MPM clinical cardiologist in charge of CMR in AC patients; SR cardiovascular
pathologist in charge of the study of sudden death in the young; AZ clinical
cardiologist in charge of second and third level screening of competitive
athletes; LD clinical cardiologist in charge of family screening; DC clinical
cardiologist in charge of competitive athletes investigation and of risk
stratification in AC patients; CB cardiovascular pathologist in charge of the
registry of sudden cardiac death in the young and tissue bank of AC, wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work has been supported by TRANSAC, University of Padua Strategic
Project CPDA133979/13, Padua, Italy; Registry for Cardio-cerebro-vascular
Pathology, Veneto Region, Venice, Italy; Target Project, Regional Health System,
Venice, Italy; PRIN Ministry of Education, University and Research 2010BWY8E9_004,
Rome, Italy; University Research Grant CPDA144300, Padua, Italy.
Received: 2 December 2015 Accepted: 16 March 2016
References
1. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy
and sudden death in young people. N Engl J Med. 1988;318:129–33.
2. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M.
Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or
myocarditis? Circulation. 1996;94:983–91.
3. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right
ventricular cardiomyopathy. Lancet. 2009;373:1289–300.
4. Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic
cardiomyopathy. Nat Rev Cardiol. 2011;9:223–33.
5. Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, Daliento L,
Buja G, Corrado D, Danieli GA, Thiene G. Clinical profile and long-term
follow-up of 37 families with arrhythmogenic right ventricular
cardiomyopathy. J Am Coll Cardiol. 2000;36:2226–33.
6. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity
enhance the risk of sudden death in adolescents and young adults? J Am
Coll Cardiol. 2003;42:1959–63.
7. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden
cardiovascular death in young competitive athletes after implementation of a
preparticipation screening program. JAMA. 2006;296:1593–601.
8. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H,
Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard
MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G,
Pilichou et al. Orphanet Journal of Rare Diseases  (2016) 11:33 Page 15 of 17Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic
right ventricular cardiomyopathy/dysplasia: proposed modification of the Task
Force Criteria. Eur Heart J. 2010;31:806–14.
9. Basso C, Corrado D, Thiene G. Arrhythmogenic right ventricular
cardiomyopathy: what’s in a name? From a congenital defect
(dysplasia) to a genetically determined cardiomyopathy (dystrophy).
Am J Cardiol. 2010;106:275–7.
10. Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular
cardiomyopathy/dysplasia – recent advances. Milano: Springer; 2007.
11. Thiene G. The research venture in arrhythmogenic right ventricular
cardiomyopathy: a paradigm of translational medicine. Eur Heart J.
2015;36:837–46.
12. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J,
Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the
1995 World Health Organization/International Society and Federation of
Cardiology Task Force on the Definition and Classification of
cardiomyopathies. Circulation. 1996;93:841–2.
13. Uhl HS. A previously undescribed congenital malformation of the heart:
almost total absence of the myocardium of the right ventricle. Bull Johns
Hopkins Hosp. 1952;91:197–209.
14. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C,
Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation.
1982;65:384–98.
15. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A,
Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK, Fontaine G, Camerini F.
Spectrum of clinicopathologic manifestations of arrhythmogenic right
ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol.
1997;30:1512–20.
16. Basso C, Thiene G. Adipositas cordis, fatty infiltration of the right ventricle,
and arrhythmogenic right ventricular cardiomyopathy. Just a matter of fat?
Cardiovasc Pathol. 2005;14:37–41.
17. Basso C, Burke M, Fornes P, Gallagher PJ, de Gouveia RH, Sheppard M,
Thiene G, van der Wal A. Guidelines for autopsy investigation of sudden
cardiac death. Virchows Arch. 2008;452:11–8.
18. Thiene G, Corrado D, Nava A, Rossi L, Poletti A, Boffa GM, Daliento L,
Pennelli N. Right ventricular cardiomyopathy: is there evidence of an
inflammatory aetiology? Eur Heart J. 1991;12(Suppl D):22–5.
19. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence
of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med.
1996;335:1190–6.
20. Valente M, Calabrese F, Thiene G, Angelini A, Basso C, Nava A, Rossi L.
In vivo evidence of apoptosis in arrhythmogenic right ventricular
cardiomyopathy. Am J Pathol. 1998;152:479–84.
21. Pilichou K, Remme CA, Basso C, Campian ME, Rizzo S, Barnett P, Scicluna BP,
Bauce B, van den Hoff MJ, de Bakker JM, Tan HL, Valente M, Nava A, Wilde
AA, Moorman AF, Thiene G, Bezzina CR. Myocyte necrosis underlies
progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic
right ventricular cardiomyopathy. J Exp Med. 2009;206:1787–802.
22. Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right
ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiovasc
Pathol. 2006;15:11–7.
23. Daliento L, Turrini P, Nava A, Rizzoli G, Angelini A, Buja G, Scognamiglio
R, Thiene G. Arrhythmogenic right ventricular cardiomyopathy in young
versus adult patients: similarities and differences. J Am Coll Cardiol.
1995;25:655–64.
24. Thiene G, Nava A, Angelini A, Daliento L, Scognamiglio R, Corrado D.
Anatomoclinical aspects of arrhythmogenic right ventricular
cardiomyopathy. In: Baroldi G, Camerini F, Goodwin JF, editors. Advances in
cardiomyopathies. Milano: Springer Verlag; 1990. p. 397–408.
25. Lemola K, Brunckhorst C, Helfenstein U, Oechslin E, Jenni R, Duru F.
Predictors of adverse outcome in patients with arrhythmogenic right
ventricular dysplasia/cardiomyopathy: long term experience of a tertiary
care centre. Heart. 2005;91:1167–72.
26. Buja G, Estes 3rd NA, Wichter T, Corrado D, Marcus F, Thiene G.
Arrhythmogenic right ventricular cardiomyopathy/dysplasia: risk
stratification and therapy. Prog Cardiovasc Dis. 2008;50:282–93.
27. Basso C, Corrado D, Bauce B, Thiene G. Arrhythmogenic right ventricular
cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5:1233–46.
28. Rizzo S, Lodder EM, Verkerk AO, Wolswinkel R, Beekman L, Pilichou K,
Basso C, Remme CA, Thiene G, Bezzina CR. Intercalated disc
abnormalities, reduced Na(+) current density, and conduction slowingin desmoglein-2 mutant mice prior to cardiomyopathic changes.
Cardiovasc Res. 2012;95:409–18.
29. Cerrone M, Noorman M, Lin X, Chkourko H, Liang FX, van der Nagel R,
Hund T, Birchmeier W, Mohler P, van Veen TA, van Rijen HV, Delmar M.
Sodium current deficit and arrhythmogenesis in a murine model of
plakophilin-2 haploinsufficiency. Cardiovasc Res. 2012;95:460–8.
30. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C,
Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular
dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and
Pericardial Disease of the European Society of Cardiology and of the
Scientific Council on Cardiomyopathies of the International Society and
Federation of Cardiology. Br Heart J. 1994;71:215–8.
31. Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, Frigo G, Malacrida S,
Settimo L, Danieli G, Thiene G, Nava A. Clinical profile of four families with
arrhythmogenic right ventricular cardiomyopathy caused by dominant
desmoplakin mutations. Eur Heart J. 2005;26:1666–75.
32. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ.
Clinical and genetic characterization of families with arrhythmogenic right
ventricular dysplasia/cardiomyopathy provides novel insights into patterns
of disease expression. Circulation. 2007;115:1710–20.
33. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D,
Pennell DJ, McKenna WJ. Left-dominant arrhythmogenic cardiomyopathy:
an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175–87.
34. Perazzolo Marra M, Leoni L, Bauce B, Corbetti F, Zorzi A, Migliore F,
Silvano M, Rigato I, Tona F, Tarantini G, Cacciavillani L, Basso C, Buja G,
Thiene G, Iliceto S, Corrado D. Imaging study of ventricular scar in
arrhythmogenic right ventricular cardiomyopathy: comparison of
3D standard electroanatomical voltage mapping and contrast-
enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol.
2012;5:91–100.
35. Perazzolo Marra M, Rizzo S, Bauce B, De Lazzari M, Pilichou K, Corrado D,
Thiene G, Iliceto S, Basso C. Arrhythmogenic right ventricular
cardiomyopathy: Contribution of cardiac magnetic resonance imaging to
the diagnosis. Herz. 2015;40:600–6.
36. Corrado D, Basso C, Leoni L, Tokajuk B, Turrini P, Bauce B, Migliore F, Pavei
A, Tarantini G, Napodano M, Ramondo A, Buja G, Iliceto S, Thiene G. Three-
dimensional electroanatomical voltage mapping and histologic evaluation
of myocardial substrate in right ventricular outflow tract tachycardia. J Am
Coll Cardiol. 2008;51:731–9.
37. Basso C, Ronco F, Marcus F, Abudureheman A, Rizzo S, Frigo AC, Bauce B,
Maddalena F, Nava A, Corrado D, Grigoletto F, Thiene G. Quantitative
assessment of endomyocardial biopsy in arrhythmogenic right ventricular
cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur
Heart J. 2008;29:2760–71.
38. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, Tarantini G,
Napodano M, Turrini P, Ramondo A, Daliento L, Nava A, Buja G, Iliceto S,
Thiene G. Three-dimensional electroanatomic voltage mapping increases
accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/
dysplasia. Circulation. 2005;111:3042–50.
39. Migliore F, Zorzi A, Silvano M, Bevilacqua M, Leoni L, Marra MP, Elmaghawry
M, Brugnaro L, Dal Lin C, Bauce B, Rigato I, Tarantini G, Basso C, Buja G,
Thiene G, Iliceto S, Corrado D. Prognostic value of endocardial voltage
mapping in patients with arrhythmogenic right ventricular cardiomyopathy/
dysplasia. Circ Arrhythm Electrophysiol. 2013;6:167–76.
40. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J,
Macisaac AI, Heidbüchel H, Prior DL. Exercise-induced right ventricular
dysfunction and structural remodelling in endurance athletes. Eur Heart
J. 2012;33:998–1006.
41. Zaidi A, Sheikh N, Jongman JK, Gati S, Panoulas VF, Carr-White G, Papadakis
M, Sharma R, Behr ER, Sharma S. Clinical Differentiation Between Physiological
Remodeling and Arrhythmogenic Right Ventricular Cardiomyopathy in Athletes
With Marked Electrocardiographic Repolarization Anomalies. J Am Coll Cardiol.
2015;65:2702–11.
42. Nava A, Thiene G, Canciani B, Scognamiglio R, Daliento L, Buja G, Martini B,
Stritoni P, Fasoli G. Familial occurrence of right ventricular dysplasia: a study
involving nine families. J Am Coll Cardiol. 1988;12:1222–8.
43. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar
A, Norman M, Baboonian C, Jeffery S, McKenna WJ. Identification of a
deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy
with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet.
2000;355:2119–24.
Pilichou et al. Orphanet Journal of Rare Diseases  (2016) 11:33 Page 16 of 1744. Protonotarios N, Tsatsopoulou A, Patsourakos P, Alexopoulos D, Gezerlis P,
Simitsis S, Scampardonis G. Cardiac abnormalities in familial palmoplantar
keratosis. Br Heart J. 1986;56:321–6.
45. Norgett EE, Hatsell SJ, Carvajal-Huerta L, Cabezas JC, Common J, Purkis PE,
Whittock N, Leigh IM, Stevens HP, Kelsell DP. Recessive mutation in
desmoplakin disrupts desmoplakin-intermediate filament interactions and
causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol
Genet. 2000;9:2761–6.
46. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R,
Simionati B, Basso C, Thiene G, Towbin JA, Danieli GA. Mutation in human
desmoplakin domain binding to plakoglobin causes a dominant form
of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet.
2002;71:1200–6.
47. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman
BB, Markowitz SM, Ellinor PT, MacRae CA, Peters S, Grossmann KS,
Drenckhahn J, Michely B, Sasse-Klaassen S, Birchmeier W, Dietz R, Breithardt
G, Schulze-Bahr E, Thierfelder L. Mutations in the desmosomal protein
plakophilin-2 are common in arrhythmogenic right ventricular
cardiomyopathy. Nat Genet. 2005;37:106.
48. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G,
Vettori A, Valente M, Towbin J, Thiene G, Danieli GA, Rampazzo A. Mutations
in desmoglein-2 gene are associated with arrhythmogenic right ventricular
cardiomyopathy. Circulation. 2006;113:1171–9.
49. Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S,
McKenna WJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy
associated with mutations in the desmosomal gene desmocollin-2. Am J
Hum Genet. 2006;79:978–84.
50. Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel
dominant mutation in plakoglobin causes arrhythmogenic right ventricular
cardiomyopathy. Am J Hum Genet. 2007;81:964–73.
51. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM,
Drenckhahn JD, Kupprion C, Ramadanova K, Thierfelder L, McKenna W,
Gallagher B, Morris-Larkin L, Bassett AS, Parfrey PS, Young TL.
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully
penetrant, lethal arrhythmic disorder caused by a missense mutation in
the TMEM43 gene. Am J Hum Genet. 2008;82:809–21.
52. van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJ, Wiesfeld AC,
Jongbloed JD, van den Wijngaard A, Kuks JB, van Spaendonck-Zwarts KY,
Notermans N, Boven L, van den Heuvel F, Veenstra-Knol HE, Saffitz JE,
Hofstra RM, van den Berg MP. Severe cardiac phenotype with right
ventricular predominance in a large cohort of patients with a single
missense mutation in the DES gene. Heart Rhythm. 2009;6:1574–83.
53. van der Zwaag PA, Cox MG, van der Werf C, Wiesfeld AC, Jongbloed JD,
Dooijes D, Bikker H, Jongbloed R, Suurmeijer AJ, van den Berg MP,
Hofstra RM, Hauer RN, Wilde AA, van Tintelen JP. Recurrent and
founder mutations in the Netherlands: Plakophilin-2 p.Arg79X mutation
causing arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Neth Heart J. 2010;18:583–91.
54. Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F, Pinamonti B,
Salcedo EE, Sauer W, Pyxaras S, Anderson B, Simon B, Bogomolovas J, Labeit S,
Granzier H, Mestroni L. Genetic variation in titin in arrhythmogenic right
ventricular cardiomyopathy-overlap syndromes. Circulation. 2011;124:876–85.
55. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, Muir A,
Pantazis A, McKenna WJ, Elliott PM. Mutations in the Lamin A/C gene
mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J.
2012;33:1128–36.
56. van Hengel J, Calore M, Bauce B, Dazzo E, Mazzotti E, De Bortoli M,
Lorenzon A, Li Mura IE, Beffagna G, Rigato I, Vleeschouwers M, Tyberghein K,
Hulpiau P, van Hamme E, Zaglia T, Corrado D, Basso C, Thiene G, Daliento L,
Nava A, van Roy F, Rampazzo A. Mutations in the area composita
protein αT-catenin are associated with arrhythmogenic right ventricular
cardiomyopathy. Eur Heart J. 2013;34:201–10.
57. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, Bauce B, Carraro G,
Thiene G, Towbin JA, Danieli GA, Rampazzo A. Regulatory mutations in
transforming growth factor-beta3 gene cause arrhythmogenic right
ventricular cardiomyopathy type 1. Cardiovasc Res. 2005;65:366–73.
58. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G,
Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA,
Rampazzo A. Identification of mutations in the cardiac ryanodine
receptor gene in families affected with arrhythmogenic right ventricular
cardiomyopathy type 2 (ARVD2). Hum Mol Genet. 2001;10:189–94.59. Li J. Alterations in cell adhesion proteins and cardiomyopathy. World J
Cardiol. 2014;6:304–13.
60. Bauce B, Nava A, Beffagna G, Basso C, Lorenzon A, Smaniotto G, De Bortoli
M, Rigato I, Mazzotti E, Steriotis A, Marra MP, Towbin JA, Thiene G, Danieli
GA, Rampazzo A. Multiple mutations in desmosomal proteins encoding
genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart
Rhythm. 2010;7:22–9.
61. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, Migliore F,
Marra MP, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori D,
Iliceto S, Thiene G, Basso C, Corrado D. Compound and digenic
heterozygosity predicts lifetime arrhythmic outcome and sudden
cardiac death in desmosomal gene-related arrhythmogenic right
ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533–42.
62. Lazzarini E, Jongbloed JD, Pilichou K, Thiene G, Basso C, Bikker H, Charbon B,
Swertz M, van Tintelen JP, van der Zwaag PA. The ARVD/C genetic variants
database: 2014 update. Hum Mutat. 2015;36:403–10.
63. Groeneweg JA, Bhonsale A, James CA, te Riele AS, Dooijes D, Tichnell C,
Murray B, Wiesfeld AC, Sawant AC, Kassamali B, Atsma DE, Volders PG, de
Groot NM, de Boer K, Zimmerman SL, Kamel IR, van der Heijden JF,
Russell SD, Jan Cramer M, Tedford RJ, Doevendans PA, van Veen TA,
Tandri H, Wilde AA, Judge DP, van Tintelen JP, Hauer RN, Calkins H.
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients
and Family Members. Circ Cardiovasc Genet. 2015;8:437–46.
64. Haywood AF, Merner ND, Hodgkinson KA, Houston J, Syrris P, Booth V,
Connors S, Pantazis A, Quarta G, Elliott P, McKenna W, Young TL.
Recurrent missense mutations in TMEM43 (ARVD5) due to founder
effects cause arrhythmogenic cardiomyopathies in the UK and Canada.
Eur Heart J. 2013;34:1002–11.
65. Gerull B, Kirchner F, Chong JX, Tagoe J, Chandrasekharan K, Strohm O,
Waggoner D, Ober C, Duff HJ. Homozygous founder mutation in
desmocollin-2 (DSC2) causes arrhythmogenic cardiomyopathy in the
Hutterite population. Circ Cardiovasc Genet. 2013;6:327–36.
66. Xu T, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pilichou K, Scherer SE,
Saffitz J, Kravitz J, Zareba W, Danieli GA, Lorenzon A, Nava A, Bauce B,
Thiene G, Basso C, Calkins H, Gear K, Marcus F, Towbin JA. Compound and
digenic heterozygosity contributes to arrhythmogenic right ventricular
cardiomyopathy. J Am Coll Cardiol. 2010;55:587–97.
67. Bao J, Wang J, Yao Y, Wang Y, Fan X, Sun K, He DS, Marcus FI, Zhang
S, Hui R, Song L. Correlation of ventricular arrhythmias with genotype
in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc
Genet. 2013;6:552–6.
68. Kapplinger JD, Landstrom AP, Salisbury BA, Callis TE, Pollevick GD, Tester DJ,
Cox MG, Bhuiyan Z, Bikker H, Wiesfeld AC, Hauer RN, van Tintelen JP,
Jongbloed JD, Calkins H, Judge DP, Wilde AA, Ackerman MJ. Distinguishing
arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated
mutations from background genetic noise. J Am Coll Cardiol. 2011;57:2317–27.
69. Andreasen C, Nielsen JB, Refsgaard L, Holst AG, Christensen AH, Andreasen L,
Sajadieh A, Haunsø S, Svendsen JH, Olesen MS. New population-based exome
data are questioning the pathogenicity of previously cardiomyopathy-
associated genetic variants. Eur J Hum Genet. 2013;21:918–28.
70. Rasmussen TB, Nissen PH, Palmfeldt J, Gehmlich K, Dalager S, Jensen UB,
Kim WY, Heickendorff L, Mølgaard H, Jensen HK, Baandrup UT, Bross P,
Mogensen J. Truncating plakophilin-2 mutations in arrhythmogenic
cardiomyopathy are associated with protein haploinsufficiency in both
myocardium and epidermis. Circ Cardiovasc Genet. 2014;7:230–40.
71. Roberts JD, Herkert JC, Rutberg J, Nikkel SM, Wiesfeld AC, Dooijes D,
Gow RM, van Tintelen JP, Gollob MH. Detection of genomic deletions
of PKP2 in arrhythmogenic right ventricular cardiomyopathy. Clin Genet.
2013;83:452–6.
72. Li Mura IE, Bauce B, Nava A, Fanciulli M, Vazza G, Mazzotti E, Rigato I,
De Bortoli M, Beffagna G, Lorenzon A, Calore M, Dazzo E, Nobile C,
Mostacciuolo ML, Corrado D, Basso C, Daliento L, Thiene G, Rampazzo A.
Identification of a PKP2 gene deletion in a family with arrhythmogenic right
ventricular cardiomyopathy. Eur J Hum Genet. 2013;21:1226–31.
73. Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M,
Bhuiyan ZA, Wiesfeld AC, Volders PG, van Langen IM, Atsma DE, Dooijes D,
van den Wijngaard A, Houweling AC, Jongbloed JD, Jordaens L, Cramer MJ,
Doevendans PA, de Bakker JM, Wilde AA, van Tintelen JP, Hauer RN.
Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic
desmosome mutations in index-patients predict outcome of family
Pilichou et al. Orphanet Journal of Rare Diseases  (2016) 11:33 Page 17 of 17screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy
genotype-phenotype follow-up study. Circulation. 2011;123:2690–700.
74. Rigato I, Corrado D, Basso C, Zorzi A, Pilichou K, Bauce B, Thiene G.
Pharmacotherapy and other therapeutic modalities for managing
Arrhythmogenic Right Ventricular Cardiomyopathy. Cardiovasc Drugs
Ther. 2015;29:171–7.
75. Wichter T, Paul TM, Eckardt L, Gerdes P, Kirchhof P, Böcker D, Breithardt G.
Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs,
catheter ablation, or ICD? Herz. 2005;30:91–101.
76. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS,
Estes NA 3rd, Marcus F, Scheinman MM. Efficacy of antiarrhythmic drugs in
arrhythmogenic right ventricular cardiomyopathy: a report from the North
American ARVC Registry. J Am Coll Cardiol. 2009;54:609–15.
77. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ,
Judge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic
risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated
desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1290–7.
78. Ruwald AC, Marcus F, Estes 3rd NA, Link M, McNitt S, Polonsky B, Calkins H,
Towbin JA, Moss AJ, Zareba W. Association of competitive and recreational
sport participation with cardiac events in patients with arrhythmogenic
right ventricular cardiomyopathy: results from the North American
multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy.
Eur Heart J. 2015;36:1735–43.
79. Bauce B, Daliento L, Frigo G, Russo G, Nava A. Pregnancy in women with
arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet
Gynecol Reprod Biol. 2006;127:186–9.
80. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU,
Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G,
Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd,
Buja G, Thiene G. Implantable cardioverter-defibrillator therapy for
prevention of sudden death in patients with arrhythmogenic right
ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084–91.
81. Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, Tichnell C, James C,
Abraham T, Russell SD, Sinha S, Judge DP, Bluemke DA, Marine JE, Calkins H.
Longterm efficacy of catheter ablation of ventricular tachycardia in patients
with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll
Cardiol. 2007;50:432–40.
82. Arbelo E, Josephson ME. Ablation of ventricular arrhythmias in arrhythmogenic
right ventricular dysplasia. J Cardiovasc Electrophysiol. 2010;21:473–86.
83. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and
radiofrequency catheter ablation of ventricular tachycardia in right
ventricular dysplasia. J Am Coll Cardiol. 1998;32:724–8.
84. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate
and outcome with epicardial ablation of ventricular tachycardia in
arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation.
2009;120:366–75.
85. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C,
Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S,
Estes NA 3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic
implantable defibrillator in patients with arrhythmogenic right ventricular
cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained
ventricular tachycardia. Circulation. 2010;122:1144–52.
86. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D,
Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Incidence
and predictors of implantable cardioverter-defibrillator therapy in patients
with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing
implantable cardioverter-defibrillator implantation for primary prevention. J Am
Coll Cardiol. 2011;58:1485–96.
87. Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A,
Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied
C, Pelliccia A, Duru F, Protonotarios N, Estes NM 3rd, McKenna WJ, Thiene G,
Marcus FI, Calkins H. Treatment of Arrhythmogenic Right Ventricular
Cardiomyopathy/Dysplasia: An International Task Force Consensus
Statement. Circulation. 2015;132:441–53.
88. Tedford RJ, James C, Judge DP, Tichnell C, Murray B, Bhonsale A, Philips B,
Abraham T, Dalal D, Halushka MK, Tandri H, Calkins H, Russell SD. Cardiac
transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
J Am Coll Cardiol. 2012;59:289–90.
89. Guiraudon CM. Histological diagnosis of right ventricular dysplasia: a role for
electron microscopy? Eur Heart J. 1989;10(Suppl D):95–6.90. Basso C, Czarnowska E, Della Barbera M, Bauce B, Beffagna G, Wlodarska EK,
Pilichou K, Ramondo A, Lorenzon A, Wozniek O, Corrado D, Daliento L,
Danieli GA, Valente M, Nava A, Thiene G, Rampazzo A. Ultrastructural
evidence of intercalated disc remodelling in arrhythmogenic right
ventricular cardiomyopathy: an electron microscopy investigation on
endomyocardial biopsies. Eur Heart J. 2006;27:1847–54.
91. Sato PY, Coombs W, Lin X, Nekrasova O, Green KJ, Isom LL, Taffet SM,
Delmar M. Interactions between ankyrin-G, Plakophilin-2, and Connexin43
at the cardiac intercalated disc. Circ Res. 2011;109:193–201.
92. Hariharan V, Asimaki A, Michaelson JE, Plovie E, MacRae CA, Saffitz JE,
Huang H. Arrhythmogenic right ventricular cardiomyopathy mutations
alter shear response without changes in cell-cell adhesion. Cardiovasc
Res. 2014;104:280–9.
93. Asimaki A, Tandri H, Huang H, Halushka MK, Gautam S, Basso C, Thiene G,
Tsatsopoulou A, Protonotarios N, McKenna WJ, Calkins H, Saffitz JE. A new
diagnostic test for arrhythmogenic right ventricular cardiomyopathy.
N Engl J Med. 2009;360:1075–84.
94. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD,
Khoury DS, Marian AJ. Suppression of canonical Wnt/beta-catenin signaling
by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right
ventricular cardiomyopathy. J Clin Invest. 2006;116:2012–21.
95. Swope D, Li J, Muller EJ, Radice GL. Analysis of a Jup hypomorphic allele
reveals a critical threshold for postnatal viability. Genesis. 2012;50:717–27.
96. Lombardi R, Dong J, Rodriguez G, Bell A, Leung TK, Schwartz RJ, Willerson
JT, Brugada R, Marian AJ. Genetic fate mapping identifies second heart field
progenitor cells as a source of adipocytes in arrhythmogenic right
ventricular cardiomyopathy. Circ Res. 2009;104:1076–84.
97. Lombardi R, da Graca C-HM, Bell A, Fromm RR, Willerson JT, Marian AJ.
Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells
to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res.
2011;109:1342–53.
98. Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ. The
hippo pathway is activated and is a causal mechanism for adipogenesis in
arrhythmogenic cardiomyopathy. Circ Res. 2014;114:454–68.
99. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S,
Puri PL, Leone TC, Marine JE, Calkins H, Kelly DP, Judge DP, Chen HS.
Studying arrhythmogenic right ventricular dysplasia with patient-specific
iPSCs. Nature. 2013;494:105–10.
100. Wen JY, Wei CY, Shah K, Wong J, Wang C, Chen HS. Maturation-Based
Model of Arrhythmogenic Right Ventricular Dysplasia Using Patient-Specific
Induced Pluripotent Stem Cells. Circ J. 2015;79:1402–8.
101. Sommariva E, Brambilla S, Carbucicchio C, Gambini E, Meraviglia V, Dello
Russo A, Farina FM, Casella M, Catto V, Pontone G, Chiesa M, Stadiotti I,
Cogliati E, Paolin A, Ouali Alami N, Preziuso C, d’Amati G, Colombo GI,
Rossini A, Capogrossi MC, Tondo C, Pompilio G. Cardiac mesenchymal
stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy.
Eur Heart J. 2015 Nov 20 [Epub ahead of print].
102. Zhang Q, Deng C, Rao F, Modi RM, Zhu J, Liu X, Mai L, Tan H, Yu X, Lin Q,
Xiao D, Kuang S, Wu S. Silencing of desmoplakin decreases connexin43/
Nav1.5 expression and sodium current in HL‑1 cardiomyocytes. Mol Med
Rep. 2013;8:780–6.
103. Noorman M, Hakim S, Kessler E, Groeneweg JA, Cox MG, Asimaki A, van
Rijen HV, van Stuijvenberg L, Chkourko H, van der Heyden MA, Vos MA,
de Jonge N, van der Smagt JJ, Dooijes D, Vink A, de Weger RA, Varro A, de
Bakker JM, Saffitz JE, Hund TJ, Mohler PJ, Delmar M, Hauer RN, van Veen TA.
Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at
the intercalated disk in patients with arrhythmogenic cardiomyopathy. Heart
Rhythm. 2013;10:412–9.
104. Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, James CA,
Judge DP, Calkins H, Churko J, Wu JC, MacRae CA, Kléber AG, Saffitz JE.
Identification of a new modulator of the intercalated disc in a zebrafish
model of arrhythmogenic cardiomyopathy. Sci Transl Med. 2014;6:240ra74.
